BACKGROUND: To document covariates which contribute to inter-individual variability in propofol pharmacokinetics in preterm and term neonates. METHODS: Population pharmacokinetics were estimated (non-linear mixed effect modelling) based on the arterial blood samples collected in (pre)term neonates after i.v. bolus administration of propofol (3 mg kg(-1), 10 s). Covariate analysis included postmenstrual age (PMA), postnatal age (PNA), gestational age, weight, and serum creatinine. RESULTS: Two hundred and thirty-five arterial concentration-time points were collected in 25 neonates. Median weight was 2930 (range 680-4030) g, PMA 38 (27-43) weeks, and PNA 8 (1-25) days. In a three-compartment model, PMA was the most predictive covariate for clearance (P<0.001) when parameterized as [CL(std).(PMA/38)(11.5)]. Standardized propofol clearance (CL(std)) at 38 weeks PMA was 0.029 litre min(-1). The addition of a fixed value in neonates with a PNA of >/=10 days further improved the model (P<0.001) and resulted in the equation [CL(std).(PMA/38)(11.5) +0.03] for neonates >/=10 days. Values for central volume (1.32 litre), peripheral volume 1 (15.4 litre), and peripheral volume 2 (1.29 litre) were not significantly influenced by any of the covariates (P>0.001). CONCLUSIONS: PMA and PNA contribute to the inter-individual variability of propofol clearance with very fast maturation of clearance in neonatal life. This implicates that preterm neonates and neonates in the first week of postnatal life are at an increased risk for accumulation during either intermittent bolus or continuous administration of propofol.
BACKGROUND: To document covariates which contribute to inter-individual variability in propofol pharmacokinetics in preterm and term neonates. METHODS: Population pharmacokinetics were estimated (non-linear mixed effect modelling) based on the arterial blood samples collected in (pre)term neonates after i.v. bolus administration of propofol (3 mg kg(-1), 10 s). Covariate analysis included postmenstrual age (PMA), postnatal age (PNA), gestational age, weight, and serum creatinine. RESULTS: Two hundred and thirty-five arterial concentration-time points were collected in 25 neonates. Median weight was 2930 (range 680-4030) g, PMA 38 (27-43) weeks, and PNA 8 (1-25) days. In a three-compartment model, PMA was the most predictive covariate for clearance (P<0.001) when parameterized as [CL(std).(PMA/38)(11.5)]. Standardized propofol clearance (CL(std)) at 38 weeks PMA was 0.029 litre min(-1). The addition of a fixed value in neonates with a PNA of >/=10 days further improved the model (P<0.001) and resulted in the equation [CL(std).(PMA/38)(11.5) +0.03] for neonates >/=10 days. Values for central volume (1.32 litre), peripheral volume 1 (15.4 litre), and peripheral volume 2 (1.29 litre) were not significantly influenced by any of the covariates (P>0.001). CONCLUSIONS: PMA and PNA contribute to the inter-individual variability of propofol clearance with very fast maturation of clearance in neonatal life. This implicates that preterm neonates and neonates in the first week of postnatal life are at an increased risk for accumulation during either intermittent bolus or continuous administration of propofol.
Authors: Chenguang Wang; Mariska Y M Peeters; Karel Allegaert; Heleen J Blussé van Oud-Alblas; Elke H J Krekels; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe Journal: Pharm Res Date: 2012-06 Impact factor: 4.200
Authors: Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez Journal: Expert Rev Clin Pharmacol Date: 2011-09 Impact factor: 5.045
Authors: Mariska Y M Peeters; Karel Allegaert; Heleen J Blussé van Oud-Alblas; Massimo Cella; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe Journal: Clin Pharmacokinet Date: 2010-04 Impact factor: 6.447